Patents by Inventor Yasuhiro Murakawa

Yasuhiro Murakawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for decoding base sequence of nucleic acid corresponding to end region of RNA and method for analyzing DNA element
    Patent number: 11312991
    Abstract: The present invention provides an analysis method by which a DNA element can be identified with higher sensitivity, and a transcription amount of the DNA element can be determined.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: April 26, 2022
    Assignee: KABUSHIKI KAISHA DNAFORM
    Inventors: Yasuhiro Murakawa, Yujiro Takegami
  • Oligonucleotide targeted to the A20-3? untranslated region
    Patent number: 10731163
    Abstract: An antisense oligonucleotide comprising a sequence targeted to the 3? untranslated region (3? UTR) of the TNFAIP3 (A20) transcript and its use as a medicament, for example in the treatment of cancer or an autoimmune disease.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: August 4, 2020
    Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
    Inventors: Markus Landthaler, Yasuhiro Murakawa
  • METHOD FOR DECODING BASE SEQUENCE OF NUCLEIC ACID CORRESPONDING TO END REGION OF RNA AND METHOD FOR ANALYZING DNA ELEMENT
    Publication number: 20190032127
    Abstract: The present invention provides an analysis method by which a DNA element can be identified with higher sensitivity, and a transcription amount of the DNA element can be determined.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 31, 2019
    Inventors: Yasuhiro MURAKAWA, Yujiro TAKEGAMI
  • OLIGONUCLEOTIDE TARGETED TO THE A20-THREE PRIME UNTRANSLATED REGION
    Publication number: 20170298359
    Abstract: An antisense oligonucleotide comprising a sequence targeted to the 3? untranslated region (3? UTR) of the TNFAIP3 (A20) transcript and its use as a medicament, for example in the treatment of cancer or an autoimmune disease.
    Type: Application
    Filed: September 2, 2015
    Publication date: October 19, 2017
    Inventors: Markus Landthaler, Yasuhiro Murakawa